Market revenue in 2023 | USD 1,345.5 million |
Market revenue in 2030 | USD 2,405.7 million |
Growth rate | 8.7% (CAGR from 2023 to 2030) |
Largest segment | Anti-vegf agents |
Fastest growing segment | Gene & Cell Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-inflammatory, Anti-glaucoma, Gene & Cell Therapy |
Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 32.86% in 2023. Horizon Databook has segmented the UK ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-inflammatory, anti-glaucoma, gene & cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
In the UK, inherited retinal disorders are the major cause of blindness in the working-age population. Retinitis pigmentosa is the most prevalent inherited eye disorder, affecting around one in every 4,000 persons in the UK.
Moreover, according to data published by eyecare expert, Théa UK, an estimated 34% of the total population in the UK, representing one in every three people, is diagnosed with dry eye disease.
Horizon Databook provides a detailed overview of country-level data and insights on the UK ophthalmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into UK ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account